APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Generic Injectables

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

Selected research

Market Analysis & Forecast

Global Generic Injectables Market Analysis and Forecast 2026-2032

Report ID 173894270228 December 2025196 pages

Choose your research edition.

Industry ResearchGeneric Injectables Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Generic Injectables Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Generic Injectables Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Generic Injectables Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Generic Injectables Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

Read the full market overview

Report Includes

This report presents an overview of global market for Generic Injectables, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Generic Injectables, also provides the revenue of main regions and countries. Of the upcoming market potential for Generic Injectables, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Generic Injectables revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Generic Injectables market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Generic Injectables revenue, projected growth trends, production technology, application and end-user industry.

Generic Injectables Segment by Company

Hospira (Pfizer Inc.)

Fresenius Kabi

Sandoz (Novartis)

Hikma Pharmaceuticals PLC

Dr. Reddy’s Laboratories Ltd

Grifols

Nichi-Iko Group (Sagent)

Teva Pharmaceutical

Auromedics

Sanofi

Gland Pharma

Endo International PLC

Generic Injectables Segment by Type

Small Molecule

Large Molecule

Generic Injectables Segment by Application

Oncology

Anesthesia

Anti-Infectives

Parenteral Nutrition

Cardiovascular Diseases

Generic Injectables Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Generic Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectables.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Generic Injectables in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Generic Injectables company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Injectables revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Generic Injectables Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Small Molecule Major Player Table 3. Large Molecule Major Player Table 4. Global Generic Injectables Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Oncology Major Player Table 6. Anesthesia Major Player Table 7. Anti-Infectives Major Player Table 8. Parenteral Nutrition Major Player Table 9. Cardiovascular Diseases Major Player Table 10. Generic Injectables Industry Trends Table 11. Generic Injectables Industry Drivers Table 12. Generic Injectables Industry Opportunities and Challenges Table 13. Generic Injectables Industry Restraints Table 14. Global Generic Injectables Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Generic Injectables Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Generic Injectables Market Share by Region (2021-2026) Table 17. Global Generic Injectables Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Generic Injectables Market Share by Region (2027-2032) Table 19. Global Generic Injectables Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Generic Injectables Revenue Market Share by Players (2021-2026) Table 21. Global Generic Injectables Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Generic Injectables Key Players Headquarters & Area Served Table 23. Global Generic Injectables Players, Product Type & Application Table 24. Global Generic Injectables Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Generic Injectables by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Generic Injectables Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Generic Injectables Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Generic Injectables Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Generic Injectables Revenue Market Share by Type (2021-2026) Table 31. Global Generic Injectables Revenue Market Share by Type (2027-2032) Table 32. Global Generic Injectables Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Generic Injectables Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Generic Injectables Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Generic Injectables Revenue Market Share by Application (2021-2026) Table 36. Global Generic Injectables Revenue Market Share by Application (2027-2032) Table 37. Hospira (Pfizer Inc.) Company Information Table 38. Hospira (Pfizer Inc.) Business Overview Table 39. Hospira (Pfizer Inc.) Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Hospira (Pfizer Inc.) Generic Injectables Product Portfolio Table 41. Hospira (Pfizer Inc.) Recent Development Table 42. Fresenius Kabi Company Information Table 43. Fresenius Kabi Business Overview Table 44. Fresenius Kabi Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Fresenius Kabi Generic Injectables Product Portfolio Table 46. Fresenius Kabi Recent Development Table 47. Sandoz (Novartis) Company Information Table 48. Sandoz (Novartis) Business Overview Table 49. Sandoz (Novartis) Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Sandoz (Novartis) Generic Injectables Product Portfolio Table 51. Sandoz (Novartis) Recent Development Table 52. Hikma Pharmaceuticals PLC Company Information Table 53. Hikma Pharmaceuticals PLC Business Overview Table 54. Hikma Pharmaceuticals PLC Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio Table 56. Hikma Pharmaceuticals PLC Recent Development Table 57. Dr. Reddy’s Laboratories Ltd Company Information Table 58. Dr. Reddy’s Laboratories Ltd Business Overview Table 59. Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio Table 61. Dr. Reddy’s Laboratories Ltd Recent Development Table 62. Grifols Company Information Table 63. Grifols Business Overview Table 64. Grifols Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Grifols Generic Injectables Product Portfolio Table 66. Grifols Recent Development Table 67. Nichi-Iko Group (Sagent) Company Information Table 68. Nichi-Iko Group (Sagent) Business Overview Table 69. Nichi-Iko Group (Sagent) Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio Table 71. Nichi-Iko Group (Sagent) Recent Development Table 72. Teva Pharmaceutical Company Information Table 73. Teva Pharmaceutical Business Overview Table 74. Teva Pharmaceutical Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Teva Pharmaceutical Generic Injectables Product Portfolio Table 76. Teva Pharmaceutical Recent Development Table 77. Auromedics Company Information Table 78. Auromedics Business Overview Table 79. Auromedics Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Auromedics Generic Injectables Product Portfolio Table 81. Auromedics Recent Development Table 82. Sanofi Company Information Table 83. Sanofi Business Overview Table 84. Sanofi Generic Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Sanofi Generic Injectables Product Portfolio Table 86. Sanofi Recent Development Table 87. Gland Pharma Company Information Table 88. Gland Pharma Business Overview Table 89. Gland Pharma Generic Injectables Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Gland Pharma Generic Injectables Product Portfolio Table 91. Gland Pharma Recent Development Table 92. Endo International PLC Company Information Table 93. Endo International PLC Business Overview Table 94. Endo International PLC Generic Injectables Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Endo International PLC Generic Injectables Product Portfolio Table 96. Endo International PLC Recent Development Table 97. North America Generic Injectables Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Generic Injectables Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Generic Injectables Revenue by Application (2021-2026) & (US$ Million) Table 100. North America Generic Injectables Revenue by Application (2027-2032) & (US$ Million) Table 101. North America Generic Injectables Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. North America Generic Injectables Revenue by Country (2021-2026) & (US$ Million) Table 103. North America Generic Injectables Revenue by Country (US$ Million) & (2027-2032) Table 104. Europe Generic Injectables Revenue by Type (2021-2026) & (US$ Million) Table 105. Europe Generic Injectables Revenue by Type (2027-2032) & (US$ Million) Table 106. Europe Generic Injectables Revenue by Application (2021-2026) & (US$ Million) Table 107. Europe Generic Injectables Revenue by Application (2027-2032) & (US$ Million) Table 108. Europe Generic Injectables Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Europe Generic Injectables Revenue by Country (2021-2026) & (US$ Million) Table 110. Europe Generic Injectables Revenue by Country (US$ Million) & (2027-2032) Table 111. China Generic Injectables Revenue by Type (2021-2026) & (US$ Million) Table 112. China Generic Injectables Revenue by Type (2027-2032) & (US$ Million) Table 113. China Generic Injectables Revenue by Application (2021-2026) & (US$ Million) Table 114. China Generic Injectables Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Generic Injectables Revenue by Type (2021-2026) & (US$ Million) Table 116. Asia Generic Injectables Revenue by Type (2027-2032) & (US$ Million) Table 117. Asia Generic Injectables Revenue by Application (2021-2026) & (US$ Million) Table 118. Asia Generic Injectables Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia Generic Injectables Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Asia Generic Injectables Revenue by Region (US$ Million) & (2021-2026) Table 121. Asia Generic Injectables Revenue by Region (US$ Million) & (2027-2032) Table 122. SAMEA Generic Injectables Revenue by Type (2021-2026) & (US$ Million) Table 123. SAMEA Generic Injectables Revenue by Type (2027-2032) & (US$ Million) Table 124. SAMEA Generic Injectables Revenue by Application (2021-2026) & (US$ Million) Table 125. SAMEA Generic Injectables Revenue by Application (2027-2032) & (US$ Million) Table 126. SAMEA Generic Injectables Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. SAMEA Generic Injectables Revenue by Country (2021-2026) & (US$ Million) Table 128. SAMEA Generic Injectables Revenue by Country (US$ Million) & (2027-2032) Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Generic Injectables Image Figure 2. Global Generic Injectables Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Generic Injectables Market Size Share 2021 VS 2025 VS 2032 Figure 4. Small Molecule Image Figure 5. Large Molecule Image Figure 6. Global Generic Injectables Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Generic Injectables Market Size Share 2021 VS 2025 VS 2032 Figure 8. Oncology Image Figure 9. Anesthesia Image Figure 10. Anti-Infectives Image Figure 11. Parenteral Nutrition Image Figure 12. Cardiovascular Diseases Image Figure 13. Global Generic Injectables Market Size (US$ Million) & (2021-2032) Figure 14. Global Generic Injectables Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Generic Injectables Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Generic Injectables Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Generic Injectables Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Generic Injectables Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Generic Injectables Revenue Market Share by Type (2021-2032) Figure 21. Global Generic Injectables Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Generic Injectables Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Generic Injectables Revenue Market Share by Application (2021-2032) Figure 24. North America Generic Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Generic Injectables Revenue Share by Type (2021-2032) Figure 26. North America Generic Injectables Revenue Share by Application (2021-2032) Figure 27. North America Generic Injectables Revenue Share by Country (2021-2032) Figure 28. United States Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Generic Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Generic Injectables Revenue Share by Type (2021-2032) Figure 33. Europe Generic Injectables Revenue Share by Application (2021-2032) Figure 34. Europe Generic Injectables Revenue Share by Country (2021-2032) Figure 35. Germany Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Generic Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Generic Injectables Revenue Share by Type (2021-2032) Figure 45. China Generic Injectables Revenue Share by Application (2021-2032) Figure 46. Asia Generic Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Generic Injectables Revenue Share by Type (2021-2032) Figure 48. Asia Generic Injectables Revenue Share by Application (2021-2032) Figure 49. Asia Generic Injectables Revenue Share by Region (2021-2032) Figure 50. Japan Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Generic Injectables Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Generic Injectables Revenue Share by Type (2021-2032) Figure 58. SAMEA Generic Injectables Revenue Share by Application (2021-2032) Figure 59. SAMEA Generic Injectables Revenue Share by Country (2021-2032) Figure 60. Brazil Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Generic Injectables Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule
  • Large Molecule
Applications
  • Oncology
  • Anesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular Diseases
Companies covered
  • Hospira (Pfizer Inc.)
  • Fresenius Kabi
  • Sandoz (Novartis)
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd
  • Grifols
  • Nichi-Iko Group (Sagent)
  • Teva Pharmaceutical
  • Auromedics
  • Sanofi
  • Gland Pharma
  • Endo International PLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Generic Injectables Market by Type
  3. 1.2.1 Global Generic Injectables Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Small Molecule
  5. 1.2.3 Large Molecule
  6. 1.3 Generic Injectables Market by Application
  7. 1.3.1 Global Generic Injectables Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Oncology
  9. 1.3.3 Anesthesia
  10. 1.3.4 Anti-Infectives
  11. 1.3.5 Parenteral Nutrition
  12. 1.3.6 Cardiovascular Diseases
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Generic Injectables Market Dynamics
  1. 2.1 Generic Injectables Industry Trends
  2. 2.2 Generic Injectables Industry Drivers
  3. 2.3 Generic Injectables Industry Opportunities and Challenges
  4. 2.4 Generic Injectables Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Generic Injectables Market Perspective (2021-2032)
  2. 3.2 Global Generic Injectables Growth Trends by Region
  3. 3.2.1 Global Generic Injectables Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Generic Injectables Market Size by Region (2021-2026)
  5. 3.2.3 Global Generic Injectables Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Generic Injectables Revenue by Players
  2. 4.1.1 Global Generic Injectables Revenue by Players (2021-2026)
  3. 4.1.2 Global Generic Injectables Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Generic Injectables Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Generic Injectables Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Generic Injectables Key Players Headquarters & Area Served
  7. 4.4 Global Generic Injectables Players, Product Type & Application
  8. 4.5 Global Generic Injectables Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Generic Injectables Market CR5 and HHI
  11. 4.6.3 2025 Generic Injectables Tier 1, Tier 2, and Tier 3
5 Generic Injectables Market Size by Type
  1. 5.1 Global Generic Injectables Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Generic Injectables Revenue by Type (2021-2032)
  3. 5.3 Global Generic Injectables Revenue Market Share by Type (2021-2032)
6 Generic Injectables Market Size by Application
  1. 6.1 Global Generic Injectables Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Generic Injectables Revenue by Application (2021-2032)
  3. 6.3 Global Generic Injectables Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Hospira (Pfizer Inc.)
  2. 7.1.1 Hospira (Pfizer Inc.) Company Information
  3. 7.1.2 Hospira (Pfizer Inc.) Business Overview
  4. 7.1.3 Hospira (Pfizer Inc.) Generic Injectables Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Hospira (Pfizer Inc.) Generic Injectables Product Portfolio
  6. 7.1.5 Hospira (Pfizer Inc.) Recent Developments
  7. 7.2 Fresenius Kabi
  8. 7.2.1 Fresenius Kabi Company Information
  9. 7.2.2 Fresenius Kabi Business Overview
  10. 7.2.3 Fresenius Kabi Generic Injectables Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Fresenius Kabi Generic Injectables Product Portfolio
  12. 7.2.5 Fresenius Kabi Recent Developments
  13. 7.3 Sandoz (Novartis)
  14. 7.3.1 Sandoz (Novartis) Company Information
  15. 7.3.2 Sandoz (Novartis) Business Overview
  16. 7.3.3 Sandoz (Novartis) Generic Injectables Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sandoz (Novartis) Generic Injectables Product Portfolio
  18. 7.3.5 Sandoz (Novartis) Recent Developments
  19. 7.4 Hikma Pharmaceuticals PLC
  20. 7.4.1 Hikma Pharmaceuticals PLC Company Information
  21. 7.4.2 Hikma Pharmaceuticals PLC Business Overview
  22. 7.4.3 Hikma Pharmaceuticals PLC Generic Injectables Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio
  24. 7.4.5 Hikma Pharmaceuticals PLC Recent Developments
  25. 7.5 Dr. Reddy’s Laboratories Ltd
  26. 7.5.1 Dr. Reddy’s Laboratories Ltd Company Information
  27. 7.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
  28. 7.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio
  30. 7.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
  31. 7.6 Grifols
  32. 7.6.1 Grifols Company Information
  33. 7.6.2 Grifols Business Overview
  34. 7.6.3 Grifols Generic Injectables Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Grifols Generic Injectables Product Portfolio
  36. 7.6.5 Grifols Recent Developments
  37. 7.7 Nichi-Iko Group (Sagent)
  38. 7.7.1 Nichi-Iko Group (Sagent) Company Information
  39. 7.7.2 Nichi-Iko Group (Sagent) Business Overview
  40. 7.7.3 Nichi-Iko Group (Sagent) Generic Injectables Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio
  42. 7.7.5 Nichi-Iko Group (Sagent) Recent Developments
  43. 7.8 Teva Pharmaceutical
  44. 7.8.1 Teva Pharmaceutical Company Information
  45. 7.8.2 Teva Pharmaceutical Business Overview
  46. 7.8.3 Teva Pharmaceutical Generic Injectables Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Teva Pharmaceutical Generic Injectables Product Portfolio
  48. 7.8.5 Teva Pharmaceutical Recent Developments
  49. 7.9 Auromedics
  50. 7.9.1 Auromedics Company Information
  51. 7.9.2 Auromedics Business Overview
  52. 7.9.3 Auromedics Generic Injectables Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Auromedics Generic Injectables Product Portfolio
  54. 7.9.5 Auromedics Recent Developments
  55. 7.10 Sanofi
  56. 7.10.1 Sanofi Company Information
  57. 7.10.2 Sanofi Business Overview
  58. 7.10.3 Sanofi Generic Injectables Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sanofi Generic Injectables Product Portfolio
  60. 7.10.5 Sanofi Recent Developments
  61. 7.11 Gland Pharma
  62. 7.11.1 Gland Pharma Company Information
  63. 7.11.2 Gland Pharma Business Overview
  64. 7.11.3 Gland Pharma Generic Injectables Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Gland Pharma Generic Injectables Product Portfolio
  66. 7.11.5 Gland Pharma Recent Developments
  67. 7.12 Endo International PLC
  68. 7.12.1 Endo International PLC Company Information
  69. 7.12.2 Endo International PLC Business Overview
  70. 7.12.3 Endo International PLC Generic Injectables Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Endo International PLC Generic Injectables Product Portfolio
  72. 7.12.5 Endo International PLC Recent Developments
8 North America
  1. 8.1 North America Generic Injectables Revenue (2021-2032)
  2. 8.2 North America Generic Injectables Revenue by Type (2021-2032)
  3. 8.2.1 North America Generic Injectables Revenue by Type (2021-2026)
  4. 8.2.2 North America Generic Injectables Revenue by Type (2027-2032)
  5. 8.3 North America Generic Injectables Revenue Share by Type (2021-2032)
  6. 8.4 North America Generic Injectables Revenue by Application (2021-2032)
  7. 8.4.1 North America Generic Injectables Revenue by Application (2021-2026)
  8. 8.4.2 North America Generic Injectables Revenue by Application (2027-2032)
  9. 8.5 North America Generic Injectables Revenue Share by Application (2021-2032)
  10. 8.6 North America Generic Injectables Revenue by Country
  11. 8.6.1 North America Generic Injectables Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Generic Injectables Revenue by Country (2021-2026)
  13. 8.6.3 North America Generic Injectables Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Generic Injectables Revenue (2021-2032)
  2. 9.2 Europe Generic Injectables Revenue by Type (2021-2032)
  3. 9.2.1 Europe Generic Injectables Revenue by Type (2021-2026)
  4. 9.2.2 Europe Generic Injectables Revenue by Type (2027-2032)
  5. 9.3 Europe Generic Injectables Revenue Share by Type (2021-2032)
  6. 9.4 Europe Generic Injectables Revenue by Application (2021-2032)
  7. 9.4.1 Europe Generic Injectables Revenue by Application (2021-2026)
  8. 9.4.2 Europe Generic Injectables Revenue by Application (2027-2032)
  9. 9.5 Europe Generic Injectables Revenue Share by Application (2021-2032)
  10. 9.6 Europe Generic Injectables Revenue by Country
  11. 9.6.1 Europe Generic Injectables Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Generic Injectables Revenue by Country (2021-2026)
  13. 9.6.3 Europe Generic Injectables Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Generic Injectables Revenue (2021-2032)
  2. 10.2 China Generic Injectables Revenue by Type (2021-2032)
  3. 10.2.1 China Generic Injectables Revenue by Type (2021-2026)
  4. 10.2.2 China Generic Injectables Revenue by Type (2027-2032)
  5. 10.3 China Generic Injectables Revenue Share by Type (2021-2032)
  6. 10.4 China Generic Injectables Revenue by Application (2021-2032)
  7. 10.4.1 China Generic Injectables Revenue by Application (2021-2026)
  8. 10.4.2 China Generic Injectables Revenue by Application (2027-2032)
  9. 10.5 China Generic Injectables Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Generic Injectables Revenue (2021-2032)
  2. 11.2 Asia Generic Injectables Revenue by Type (2021-2032)
  3. 11.2.1 Asia Generic Injectables Revenue by Type (2021-2026)
  4. 11.2.2 Asia Generic Injectables Revenue by Type (2027-2032)
  5. 11.3 Asia Generic Injectables Revenue Share by Type (2021-2032)
  6. 11.4 Asia Generic Injectables Revenue by Application (2021-2032)
  7. 11.4.1 Asia Generic Injectables Revenue by Application (2021-2026)
  8. 11.4.2 Asia Generic Injectables Revenue by Application (2027-2032)
  9. 11.5 Asia Generic Injectables Revenue Share by Application (2021-2032)
  10. 11.6 Asia Generic Injectables Revenue by Country
  11. 11.6.1 Asia Generic Injectables Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Generic Injectables Revenue by Country (2021-2026)
  13. 11.6.3 Asia Generic Injectables Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Generic Injectables Revenue (2021-2032)
  2. 12.2 SAMEA Generic Injectables Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Generic Injectables Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Generic Injectables Revenue by Type (2027-2032)
  5. 12.3 SAMEA Generic Injectables Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Generic Injectables Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Generic Injectables Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Generic Injectables Revenue by Application (2027-2032)
  9. 12.5 SAMEA Generic Injectables Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Generic Injectables Revenue by Country
  11. 12.6.1 SAMEA Generic Injectables Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Generic Injectables Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Generic Injectables Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst